Innovative drugs soothe Fosun Pharma from pain of fading Covid vaccine
With China's pandemic controls ending and the WHO adjusting its vaccination recommendations, demand for the company’s comirnaty vaccine is plunging Key takeaways: Fosun Pharma's net profit fell more than 20%…
Junshi Biosciences Hits Revenue Roadblock Amid Covid Drug Delay
Junshi Biosciences is facing business headwinds. Its key cancer drug has not sold as well as competing products and the company has yet to file a marketing application for its…
Genuine Biotech Seeks IPO Booster from New Oral Covid Drug
Company hopes China’s approval of its small molecule oral Covid-19 drug will draw investors to its newly filed listing plan Key Takeaways: Genuine Biotech has filed to list in Hong…
RELATED ARTICLES
-
Fosun moves on from debt crisis with renewed focus on tourism, healthcare
0656.HK -
Fosun Tourism travels back to home base with delisting plan
1992.HK 0656.HK
-
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
